Pacira BioSciences, Inc. PCRX Contingent consideration
Contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept pcrx:ContingentConsiderationNoncurrent.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s contingent consideration?
- Pacira BioSciences, Inc. (PCRX) reported contingent consideration of $15.79M in Q1 2026.
- How has Pacira BioSciences, Inc.'s contingent consideration changed year-over-year?
- Pacira BioSciences, Inc.'s contingent consideration decreased by 10.1% year-over-year, from $17.57M to $15.79M.
- What is the long-term trend for Pacira BioSciences, Inc.'s contingent consideration?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s contingent consideration has grown at a 5.8% compound annual growth rate (CAGR), from $13.61M to $18.07M.
- What does contingent consideration mean?
- This metric represents the estimated fair value of future payment obligations triggered by the achievement of specific milestones or performance targets, typically associated with past business acquisitions or licensing agreements. It serves as a liability reflecting the company's potential future cash outflows tied to the success of acquired assets or technologies. Investors track this to understand the company's future financial commitments and the risk profile associated with its inorganic growth strategy.